Dosing guidance of IMBRUVICA® + venetoclax in chronic lymphocytic leukaemia (CLL)
IMBRUVICA® + venetoclax is the only all-oral, chemo-free fixed-duration therapy that can be taken at home
IMBRUVICA® + venetoclax is administered over 15 cycles* as outlined below
Tailored to your patients’ preference for
tablets over infusion or injectionsǂ
Free patients from treatment after 15 cycles
Long-term, treatment-free holidays for your patients
What do leading experts think about the patient-tailored dosing of IMBRUVICA® + venetoclax in CLL?
A Phase III study evaluating the efficacy and safety of first-line IMBRUVICA® + venetoclax combination therapy in patients with CLL who are older and/or have comorbidities
An international multicentre Phase II study evaluating the IMBRUVICA® + venetoclax combination therapy in previously untreated CLL patients aged ≤70 years
Explore the safety of IMBRUVICA® + venetoclax
Learn about IMBRUVICA® + venetoclax in CLL
CLL=chronic lymphocytic leukaemia; TLS=tumour lysis syndrome.
*1 cycle=28 days.
†Initial 12-hour hospitalisation to monitor high-risk patients.
ǂIn a review of 13 articles on the various modes of administration for cancer treatment administration, 84.6% (11/13 articles) reported that patients preferred oral treatment over intravenous treatment.
| Adverse events should be reported. Reporting an adverse event will help J&J monitor the safety of all our healthcare products for the benefit of patients and consumers. It is important to report adverse events, even if it is a known adverse event, as this provides valuable information for monitoring product safety, allowing J&J to provide up-to-date information in the Summary of Product Characteristics and product information leaflets. For Adverse Events or safety related issues on J&J products, please approach the mailbox PVNEMA@ITS.JNJ.COM or Tel: +961 1 518769/ +961 1 518775 |
